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Purpose: This study was designed to identify significant differences in the clinical and 
radiologic haracteristics and outcome between patients with inflammatory and nonin- 
flammatory abdominal aortic aneurysms (AAAs). 
Methods: We reviewed 29 consecutive patients who underwent repair of an inflammatory 
AAA between 1985 and 1994. This group was matched in a case-control fashion by date 
of surgery and by the performing surgeon to a group of 58 patients who underwent repair 
of noninflammatory AAAs. 
Results: The two groups had comparable characteristics of age, gender, and cardiovascular 
risk factors. Patients with inflammatory AAAs were significantly more symptomatic than 
those with noninflammatory AAAs (93% vs 9%, p < 0.001), were more likely to have a 
family history of aneurysms (17% vs 1.5%, p = 0.007), and tended to be current smokers 
(45% vs 24%, p = 0.049). The most significant laboratory difference was an elevated 
sedimentation rate in patients with inflammatory AAAs (mean, 53 mm/hr  vs 12 mm/hr, 
p < 0.00001). Inflammatory AAAs also were significantly larger than noninflammatory 
AAAs at presentation (6.8 cm vs 5.9 cm, p < 0.05). Although operative mortality was low 
in both groups, patients with an inflammatory AAA tended to have higher morbidity, 
including sepsis (p < 0,01) and renal failure (p = 0.04). Five-year survival rates, however, 
were similar for the two groups (79% for inflammatory and 83% for noninflammatory 
AAAs). On follow-up computed tomographic scans, the retroperitoneal inflammatory 
process resolved completely in 53% of the patients, but 47% of patients had persistent 
inflammation that involved the ureters in 32% and resulted in long-term solitary or 
bilateral renal atrophy in 47%. 
Conclusions: This case-control study provides preliminary evidence that inflammatory 
AAAs may have a relatively strong familial connection and that current smoking may play 
an important role in the inflammatory esponse. The study also documents hat persistent 
retroperitoneal inflammation may be more prevalent than has been previously reported, 
and stresses the need for an improved understanding of the pathogenesis and long-term 
management of inflammatory AAAs. (J Vasc Surg 1996;23:860-9.) 
In 1972, Walker and colleagues ~ used the term 
"inflammatory aneurysms of the abdominal aorta" to 
describe a distinct clinical syndrome. They empha- 
sized the dense, white inflammatory wall and adhe- 
sion of some aneurysms to the adjacent duodenum 
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and ureters. Subsequent reports characterized the 
typical clinical presentation of abdominal or back 
pain, malaise, weight loss, and an elevated sedimen- 
tation rate. 2q3 One multicenter study estimated that 
such an inflammatory process is associated with 2% to 
14% of all abdominal aortic ancurysms (AAAs). l l The 
precise cause of the inflammatory process, however, 
still remains unsolved. I°a4 22 Debate also continues 
over whether the process resolves after graft place- 
ment. s'ls Some authors contend that graft repair 
results in dissipation of the inflammation, s whereas 
others report persistent inflammation in some pa- 
tients. 2a Another important question is whether pa- 
tients with inflammatory AAAs have a long-term 
survival rate different from patients with noninflam- 
matory AAAs.4 
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To address these controversies, we performed a
case-control analysis of the clinical characteristics and 
surgical outcomes for 29 patients with documented 
inflammatory AAAs and 58 control patients with 
noninflammatory AAAs. Because the late outcome of 
the retroperitoneal inflammation has received mini- 
mal documentation in the literature, 2awe also ascer- 
tained the course of the inflammatory process by 
comparing preoperative imaging studies with postop- 
erative computed tomographic (CT) scans at various 
times of follow-up. 
METHODS 
We reviewed the medical records of 29 consecu- 
tive patients who underwent surgery for an inflam- 
matory AAA between 1985 and 1994 at the Mayo 
Clinic. We included only cases in which an inflam- 
matory AAA was diagnosed unequivocally by CT, 
ultrasound, intraoperative, and pathologic find- 
ings. 1'3'4'7a° We excluded all questionable cases of 
inflammatory AAA. In addition, 58 records of pa- 
tients with nonruptured, noninflammatory (athero- 
sclerotic) AAAs were identified in a case-control 
fashion for multiple variables comparison. Cases 
were matched by date of surgery and the performing 
surgeon. 
We ascertained clinical characteristics and risk 
factors that may have predisposed patients to the 
inflammatory process or increased surgical risk and 
decreased the survival rate. These factors included 
gender, age, smoking history, hyperlipidemia, diabe- 
tes mellitus, family history of aneurysm (parent or 
sibling), clinically evident coronary heart disease, 
history of myocardial infarction or stroke, chronic 
obstructive pulmonary disease, clinically evident pe- 
ripheral arterial occlusive disease, and chronic renal 
insufficiency (creatinine l vel >1.5 mg/dl).  
In addition, we tabulated the typical clinical symp- 
toms and signs of an inflammatory AAA: fever, 
abdominal or back pain, weight loss, tender AAA, 
elevated erythrocyte sedimentation rate (ESR), and 
abnormal serum creatinine l vel. Ultrasound and CT 
reports were reviewed to determine whether they had 
revealed the diagnosis of inflammatory AAA before 
operation. The mean diameter for both inflammatory 
and noninflammatory AAAs was compared. The ana- 
tomic extent of the inflammatory process was deter- 
mined by preoperative ultrasound scans, CT scans, 
and operative descriptions. Whether the aneurysm 
ruptured or not was also ascertained. 
Operative reports were reviewed to identify tech- 
nical differences between the management of inflam- 
matory and noninflammatory AAAs: ligation and 
division of left renal vein, tube rather than bifurcated 
aortic grafts, renal artery revascularization, renal 
stenting, and ureterolysis. Aneurysmal cultures were 
reviewed. When available, pathologic specimens were 
examined for inflammatory wall thickness and histo- 
logic signs of inflammation. Operative mortality and 
morbidity rates and late survival and complications 
were delineated. 
In all 19 cases in which preoperative and late 
postoperative imaging were retrievable, we looked 
specifically for signs of persistence orresolution of the 
inflammatory process. These studies then were re- 
viewed independently by a vascular radiologist 
(A.W.S.), who was unaware of the clinical symptom 
outcome. 
In the statistical analysis, we used either a Z 2 test 
or Fisher's exact test to test for an association be- 
tween the discrete factors of inflammatory or non- 
inflammatory AAAs. We used the Wilcoxon rank- 
sum test to analyze the association for continuous 
variables. A ICaplamMeier survival test was used to 
determine a possible difference in the patient survival 
rate between the two groups, with the p value based 
on the log-rank test. 
RESULTS 
Clinical characteristics. The two groups had 
comparable characteristics of age, gender, and medi- 
cal risk factors. Thc mean patient age was 71.7 years 
for inflammatory AAAs and 71.3 years for noninflam- 
matory AAAs. The gender mix was also comparable, 
with a male predominance of3.4 to I in both groups. 
The inflammatory AAA group included 24 men and 5 
women. When stratified according to their preopera- 
tive cardiovascular risk factors (Table I), only two 
variables achieved statistical significance. The most 
interesting was the strong familial tendency for in- 
flammatory AAAs compared with noninflammatory 
AAAs ( 17% compared with 1.5 %, p = 0.01 ). Although 
a history of cigarette smoking was comparable in the 
two groups (83% and 79%), more patients with 
inflammatory AAAs tended to be current smokers 
(45% compared with 24%, p < 0.05). 
Clinical presentation. The vast majority of pa- 
tients with inflammatory AAAs (93%) were symptom- 
atic, compared with only 9% of patients with nonin- 
flammatory AAAs (p < 0.001). The leading symptom 
of an inflammatory AAA was abdominal pain (83%), 
followed by back pain (55%) and a weight loss of at 
least 10 pounds (mean, 25 pounds) in 41% of patients 
with inflammatory AAAs. On physical examination, 
more patients with an inflammatory AAA had a tender 
abdomen (p < 0.001). Fever (>37.5 ° C) was encoun- 
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Table I. Preoperative risk factors 
Inflammatory AAA (n = 29) Noninflammatory AAA (n = 58) p 
Coronary artery disease 16 (55.2%) 32 (55.2%) 1.00 
Past myocardial infarction 9 (31%) 19 (32.8%) 0.43 
Hypertension 20 (69%) 38 (65.5%) 0.87 
Past stroke 4 (13.8%) 9 (15.5%) 0.89 
Chronic obstructive pulmonary disease 14 (48.3%) 17 (29.3%) 0.08* 
Peripheral arterial occlusive disease 7 (24.1%) 14 (24.1%) 1.00 
Hyperlipidemia 8 (27.6%) 13 (22.4%) 0.59 
Diabetes 4 (13.8%) 12 (20.7%) 0.55 
Chronic renal failure 6 (20.7%) 10 (17.2%) 0.83 
Family history of AAA 5 (17.2%) 1 (1.7%) 0.011" 
Cigarette smoker 
ever smoked 24 (82.8%) 46 (79.3%) 0.70 
current smoker 13 (44.8%) 14 (24.1%) 0.04~ 
*Borderline significant; i'statistically significant. 
Table II. Clinical outcome of inflammatory AAA syndrome (n = 29) 
n (%) 
Preoperative clinical features 
Fever (_>37.5 ° C) 13 (45%) 
Pain 25 (86%) 
Abdomen 24 (83%) 
Back 16 (55%) 
Weight loss (_>10 lb) 12 (41%) 
Elevated ESR 26 (89%) 
Serum croat±nine (->1.2 mg/dl) 16 (55%) 
Postoperative outcome 
Death 2 (6.8%) 
Resolution of pain 25 (93%) 
Resolution of fever 24 (89%) 
Serum creatinine l vel (>1.2 mg/dl) 18 (67%) 
Chronic renal failure/dialysis orureteral stent 3 (11%) 
tcred more frequently in patients with an inflamma- 
tory AAA (45% compared with 9%; p < 0.05). 
The most significant abnormality in results of 
laboratory tests was an elevated ESR in 89% of 
patients with an inflammatory AAA and in only 11% of 
patients with a noninflammatory AAA (p < 0.001). 
Mean ESRlevels were 53 + 3 mm/hr compared with 
12 ± 2 mm/hr in patients with noninflammatory 
AAAs (p < 0.0001). Similarly, white blood count was 
elevated in approximately 40% of patients with an 
inflammatory AAA Compared with 10% of patients 
with a noninflammatory AAA (p < 0.05), reaching 
means of 11,200 and 8600, respectively. Serum 
creatinine levels were similar in the two groups at 
1.4 ± 0.2 mg/dl and 1.2 ± 0.1 mg/dl for inflamma- 
tory and noninflammatory AAAs, respectively. 
The sensitivity of a preoperative imaging study for 
the correct diagnosis of an inflammatory AAA was 
90% for CT scans of the abdomen compared with 60% 
for abdominal aortic ultrasound scans (Fig. 1). An- 
giography was of no benefit for the diagnosis of an 
inflammatory AAA. The mean preoperative diameter 
was greater for the inflammatory AAAs than for the 
noninflammatory AAAs (6.8 + 0.2 cm compared with 
5.9 + 0.2 cm; p < 0.05). None of the inflammatory 
AAAs had signs of rupture before surgery. Ureteral 
involvement was noted in 32 % of patients with inflam- 
matory AAAs. Half of these patients had bilateral 
uretcral involvement. For comparison, we included 
only nonruptured, noninflammatory AAAs, although 
six (10.3%) of the originally matched noninflamma- 
tory AAAs were ruptured and were eventually ex- 
clude& None of the noninflammatory AAAs had 
ureteral involvement. 
Operative pathologic findings. All 29 patients 
with an inflammatory AAA had adjacent organ adhe- 
sion to the aneurysm (Fig. 2). The inflammatory 
aneurysm surface was distinctively white and glisten- 
ing compared with the yellowish appearance of non- 
inflammatory AAAs. The most common organs in- 
volved in the inflammatory process were the duode- 
num (100%), left renal vein (48%), and the ureters 
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Fig. 1. A, CT scan of typical thick wall of inflammatory AAA. B, Ultrasound scan shows thick 
wall ("halo") of same inflammatory AAA. C, Intraoperative findings reveal thick, white, 
glistening aneurysm wall that is usually densely adherent to duodenum, 
(45%). Other less common adhesions encountered 
were the small intestine (14%), colon and inferior vena 
cava (10% each), pancreas (7%), and common bile 
duct (3%). 
Surgical management. All aneurysms were ap- 
proached through a transperitoneal incision; none 
were exposed bya retroperitoneal incision. The extent 
of the AAA was similar in both groups, that is, 
infrarenal and iliac involvement. The use of straight 
and bifurcated grafts was also similar with approxi- 
mately equal use of both types of graft. In the 
inflammatory aneurysm group, the left renal vein was 
ligated for better exposure in only two patients. Five 
patients with inflammatory AAAs (17%) had either 
preoperative or intraoperative placement of ureteral 
stents. Only one patient underwent ureterolysis. In 
the available pathologic specimens, the inflammatory 
aneurysm wall was markedly thickened (mean, 13 +_ 
2 mm) compared with noninflammatory AAAs (4 + 
I ram; p < 0,001). The presence of germinal centers, 
lymphocytic inflammatory infiltrates, giant cells, fi- 
brosis of nerves, and perivascular inflammation were 
also significantly more common in inflammatory 
aneurysms than in noninflammatory aneurysms 
(p < 0.0001). 
Postoperative outcome (Table 2). Although the 
in-hospital mortality rate for inflammatory A2~s was 
higher than that for noninflammatory AAAs (6.8% 
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Fig. 2. Most common anatomic structures attached tothe 
inflammatory aneurysm wall (n = 29). 
and 0%, respectively), the difference did not achieve 
statistical significance. Iatrogenic ommon bile duct 
and pancreatic injury resulting in severe pancreatitis 
and bile peritonitis occurred in one patient, and 
septicemia led to the death of a second patient. The 
rate of other postoperative morbidity tended to be 
higher in patients with an inflammatory AAA com- 
pared with those who had a noninflammatory AAA 
(45% compared with 26%, p = 0.07). Patients with 
inflammatory AAAs tended to have higher rates of 
septicemia (p< 0.01) and renal failure (p= 0.04) 
than did patients with noninflammatory AM~s. Other 
early postoperative complications, which included 
myocardial infarction, stroke, respiratory failure, 
bleeding, thromboembolism, prolonged ileus, and 
wound infection, were divided equally between the 
two groups. The overall early reoperation rate was 7% 
and was similar between the two groups. 
Twenty-five of 27 survivors (93%) had resolution 
of their preoperative clinical symptoms. Long-term 
survival rates were similar for the two groups, with 
5-year ates of 79% and 83% for patients with inflam- 
matory and noninflammatory AAAs (Fig. 3). The 
only late graft infection occurred in the inflammatory 
AAA group. 
Late resolution of  inflammatory process (Table 
II). Postoperative CT or ultrasound imaging was 
available in 19 of 29 patients with an inflammatory 
AAA. The mean follow-up was 12.9 + 1.7 months 
(range, 3 to 51 months). The preoperative scans dem- 
onstrated that most of the periaortic inflammatory 
process occurs on the anterior surface of the aneurysm 
(Fig. 4), with a mean thickness of 7.6 + 0.8 mm 
(range, 3 to 15 ram). This inflammatory process had 
completely resolved at late follow-up in only 53% of 
patients. None of these patients, however, had com- 
plete resolution earlier than 4 months. Their initial 
mean aneurysmal wall thickness was 5.4 + 0.5 mm, 
with a mean resolution time of 1 year. The mean re- 
gression rate in this group was 1.5 + 0.3 mm/month.  
In contrast, 47% of patients howed a persistent but 
slowly resolving inflammatory process on scans ob- 
tained at a mean follow-up of 17.7 +_ 4.9 months 
(range, 3 to 48 months). Before surgery, the mean 
size of the inflammatory process in these patients was 
larger than patients in whom the inflammation had 
completely resolved (10.4 _+ 1.0 mm compared with 
5.4 + 0.5 ram; p < 0.01). Their regression rate was 
relatively slow (0.7 + 0.2 mm/month).  Ureteral en- 
trapment persisted in 32% of patients, with signs of 
renal atrophy in 47% of patients (Fig. 5). Chronic 
dialysis became necessary in 3.4% of patients with in- 
flammatory AAAs. At last follow-up, the patients with 
residual retroperitoneal inflammation had a mean re- 
sidual inflammatory thickness of 6.8 _+ 0.5 ram, which 
was significantly ess than the preoperative finding of 
10.4 + 1.0 mm (p < 0.05). 
DISCUSSION 
This case-control study confirms everal past ob- 
servations about inflammatoryAAAs and reveals afew 
new preliminary but provocative findings. The triad 
of abdominal or back pain, a pulsatile (and sometimes 
tender) abdominal mass, and an elevated sedimenta- 
tion rate is now the well-recognized clinical syndrome 
associated with an inflammatory aneurysmf1,4 Al- 
though frequently missed in the past, the diagnosis 
currendy can be made before surgery by the thick 
periaortic inflammatory ind that was seen in 90% of 
our patients on CT scan .  24-26 Our surgical experience 
also corroborates the technical challenge and dangers 
associated with the dense adhesions of bowel and 
veins to the inflamed aneurysm wall. These observa- 
tions are not new, but the case-control method and 
our long-term imaging studies uncovered other un- 
expected findings of clinical relevance. 
The most unexpected observation was the strong 
family tendency (17%) of inflammatory AAAs com- 
pared with noninflammatory AAAs (1.5%). Familial 
predilection has been recognized in several general 
atherosclerotic AAA series, but these reports have not 
addressed specifically the inflammatory versus nonin- 
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Fig. 3. Kaplan-Meier survival curves for inflammatory (n= 29; n = 8 at 5 years follow-up) and 
noninflammatory abdominal ortic aneurysms (n = 58; n = 19 at 5 years follow-up). 
Table I I I .  Late imaging findings (n = 19) 
n (%) 
CT scan 13 (68%) 
Ultrasonography 6 (32%) 
Residual inflammation 9 (47%) 
Ureteral involvement 6 (32%) 
Renal atrophy 9 (47%) 
Unilateral 6 (32%) 
Bilateral 3 ( 16% )
Follow-up: mean, 12.9 + 1.7 months (range, 3 to 51 months) 
flammatory nature of the aneurysms. 27-31 Because our 
previous review of inflammatory AAAs in 1985 had 
revealed a family history in 7.6% of patients, we pro- 
spectively ascertained family history (sibling or par- 
ent) in all subsequent cases both of inflammatory and 
noninflammatory AAAs. Although the numbers of 
patients we used for analysis were relatively small, the 
level of significance was strong (p = 0.01) and should 
be considered an important preliminary finding. 
Such a familial tendency for inflammatory AAAs, 
however, may imply an abnormality in the cellular or 
humoral responses of the immune system. This pro- 
vocative finding will obviously need corroboration by 
other similar case-control studies; but if it is con- 
firmed, the explanation may lie in an altered cell- 
mediated immune response similar to the recent 
findings for giant cell arteritis by Weyand et al. 32-35 In 
our pathologic omparisons, inflammatory AAAs and 
giant cell arteritis share some common pathologic 
features. 36,37 
The second significant observation of this study 
concerns moking. Several studies of inflammatory 
AAAs already have emphasized the extraordinarily 
high prevalence of cigarette abuse.4,s They have not, 
however, examined whether the patient had simply 
been a past smoker or was a current smoker. Although 
the percentage of patients who had ever smoked was 
similar for inflammatory and noninflammatory AAAs 
(8 3% and 80%, respectively), the patients with inflam- 
matory AAAs were more likely to be current smokers 
(45% compared with 24%, p = 0.04). The precise 
mechanism by which cigarette smoking may alter the 
inflammatory response is not known, but Murphy et 
al.38 have presented ata suggesting that nicotine 
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Fig. 4. Serial postoperative CT scans of inflammatory AAA in 64-year-old man. A, Six-week 
postoperative scan shows residual inflammatory rind around Dacron aortic graft. B, Nine-month 
postoperative scan shows resolution of inflammatory ind. 
Fig. 5. This 65-year-old man had a 6.8-cm inflammatoryAAA, occlusive uropathy, and a serum 
creatinine l vel of 4.7 mg/dl. A, Preoperative CT scan. B, Postoperative scan at 5 months with 
residual inflammation but entrapped ureters that required stenting. 
induces elastase release by neutrophils. Other effects 
of nicotine or tobacco components on cell prolifera- 
tion and fibrosis may also play a role in the develop- 
ment and persistence ofan inflammatory etroperito- 
neal process. The clinical implication is that smoking 
cessation may be essential in resolving the inflamma- 
tory process surrounding the AAA. Because our 
follow-up records did not contain specific informa- 
tion on continued smoking in every patient, we can 
only speculate that continued smoking may be a 
driving factor in persistent inflammation. 
Paramount to the final outcome of an inflamma- 
tory AAA is whether surgical repair by interposition 
grafting will result in resolution of the inflammatory 
process. The time-honored adage has been that 
grafting will lead to complete r solution of symptoms 
and inflammation.5 Our findings challenge this adage. 
In follow-up ranging to 4 years, we documented 
complete resolution in slightly more than half of our 
patients, whereas the remainder had slow or no 
change. Despite improved symptoms, the inflamma- 
tory process persisted. In fact, it was associated with 
ureteral entrapment in one third of patients, with 
signs of silent unilateral or bilateral renal atrophy in 
half of this subgroup. A recent report from Stella et 
al. 23 in Italy agrees with our observations. They found 
that resolution occurred when the cellular density of 
the inflammatory rind was high, that is, when the 
cell/fibrosis ratio was greater than 1. We observed 
that resolution correlated with the initial thickness of 
the wall and was more likely when the initial wall 
thickness was less than 10 mm. 
Whether the persistent inflammatory esponse can 
be modified pharmacologically remains debatable. 
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For  years, the debate has centered around the use of  
steroids, a9 but  could other mediators of  the immune 
system help with healing? The answer is not  known, 
but  the question emphasizes the need for a clearer 
del ineation o f  the pathogenesis o f  in f lammatory  
AAAs. 
One o f  the encouraging findings of  this case- 
control  study was the similar late survival for the two 
groups. A l though inf lammatory AAAs have a slightly 
higher perioperative mortal i ty rate, the late outcome 
is not  impaired in comparison with noninf lammatory 
AAAs. This observanon confirms the findings of  our 
previous Mayo Clinic series o f  inf lammatory AAAs 
that used historical controls to construct survival 
comparisons. 4 This past comparison was random and 
l imited by selection bias. Consequently,  we are more 
confident in the findings o f  this case-control  study. 
CONCLUSION 
This study raises new questions about  the familial 
tendency o f  inf lammatory AAAs and stresses the 
potential  importance of  cont inued smoldng in pre- 
venting the resolut ion o f  the retroperitoneal  inflam- 
mation. In addit ion, we have documented the persis- 
tence of  the inf lammatory response in nearly 50% of  
patients after surgical grafting. The future challenge is 
to delineate the molecular and cellular pathogenesis 
o f  inf lammatory AAAs so that better pharmacologic 
therapies can be developed for patients with the most 
exuberant inf lammatory processes. For  the moment ,  
the best management  o f  an inf lammatory AAA re- 
mains repair by inclusion grafting because it alleviates 
the clinical syndrome in the majority of  patients. 
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DISCUSSION 
Dr. Bruce L. Gewertz (Chicago, Ill.). I enjoyed this 
excellent presentation and landmark paper. A number of 
things about inflammatory aneurysms are really fascinating. 
It has been suggested that inflammatory aneurysms hold a 
key to our understanding ofaneurysms in general. They are 
obviously a small subset of aneurysms but have many 
interesting features that the Mayo Clinic group has beauti- 
fully outlined. Let me ask you a few unanswerable questions, 
with my apologies. 
You did exclude anumber of cases in which inflamma- 
tory components were present hat did not meet all the 
criteria that you rigorously set up. I think that was the right 
thing to do to gain insight into the questions you were 
asking, but many of us believe that there may be a spectrum 
of inflammatory aneurysms, from the small degree of 
inflammation i the typical aneurysm to these very pro- 
nounced inflammatory components. I wonder whether you 
think there is a spectrum, or do you think there is sort of an 
abrupt shift from a noninflammatory to an inflammatory 
aneurysm? Obviously, it begs the question of what comes 
first? Does the aneurysm come first or does the inflamma- 
tion engender some local process that results in a weakening 
of the arterial wall and aneurysmal formation? This also 
raises the issue of whether inflammatory aneurysms rupture 
at the same rate as noninflammatory aneurysms. One could 
guess that the thicker the wall the less likely it would be to 
rupture. 
Finally, the inflammation is almost always less on the 
posterior end. This fact led Bob Rutherford and many of us 
to use a retroperitoneal approach. Do you think that the 
localized nature of the reaction gives some clue as to the 
genesis of the inflammatory component? 
I will finish with a couple of practical questions that may 
help us in our management. On the basis of your experience 
and longitudinal study and the fact that persistent renal 
problems may exist, do you stent or not stent he ureters at 
the initial operation? How long do you wait to decide that 
the inflammation is not resolving and you have to intervene 
in some way with a nephrostomy or a ureteral stent? 
Secondly, because you only lysed, as I recall, one patient's 
ureter during the course of the procedures, hould we take 
a more aggressive tack, as is done overseas, to lyse the ureters 
and take the risk of inadvertent ureteral injury and devas- 
cularizarion of the ureter? Finally, I am interested in your 
thoughts on a problem that I have faced. What do you do 
when the component of inflammation is very significant in 
and around the lilac vessels and you have to go to the 
femoral vessels for whatever reason? Do you have any tricks 
in terms of tunneling to the groins? 
Dr. John W. Hallett, Jr. Studying the pathogenesis of 
inflammatory aneurysms will lead to better understanding 
of all aneurysm pathogenesis. We agree that there is a 
spectrum of inflammatory aneurysms. In this study, we 
specifically selected the advanced end of this spectrum. 
When we did our case-control match, we hoped to discover 
greater differences between oninflammatory and inflam- 
matory AAAs. 
Which comes first, the aneurysm or the inflammation? 
We have seen patients who have had an inflammatory 
response around arelatively normal-sized aorta. Over time 
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these particular patients have shown aneurysmal degenera- 
tion of that particular aorta. So in some cases, the inflam- 
mation does precede the aneurysm. 
The question about rupture is an interesting one. None 
of our 29 patients with inflammatory AAAs had a rupture. 
When we first did the case-control match, however, six of 
the 58 control aneurysms had shown signs of rupture. We 
excluded those ruptures and went to 58 nonruptured 
aneurysms for the study. In a previous tudy by Pennell et al. 
from the Mayo Clinic, rupture risk for the inflammatory 
aneurysms was one out of about 100. So the rupture risk is 
lower than noninflammatory AAAs. 
The anterior location of the inflammation is also inter- 
esting. We have seen it on the posterior aspect too, but not 
in every case. I cannot explain why one would not see some 
inflammation on the posterior aspect except hat not much 
tissue usually is present between the posterior aortic wall 
and the anterior spinal igament. 
Should we stent he ureters or not? Perhaps we should 
think more strongly about stenting. If ureters remain 
entrapped after AAA repair, aurologist should be consulted. 
The stenting should probably be done until one sees 
dissipation of the inflammation, which can take months or 
even a few years to occur. Obviously, one may not want to 
stent for a long period of time. If there is a lot of 
inflammation, you have to address the question of using 
steroids. In the future, I hope other antiinflammatory 
agents will exist that might be used. 
Should we lyse the ureters? We do not believe strongly 
at all about lysing the ureters. In fact, performing ureteroly- 
sis can be a very risky thing to do. Thus we would not 
recommend routine lysis. 
In terms of tunneling the graft limbs, most of these 
aneurysms have dissipation of the inflammation at the iliac 
artery level. If  the inflammation extends into the pelvis, 
however, one alternative is to bring one graft limb down one 
side of the abdomen (e.g., the left side) to the external i iac 
artery and then do a femorofcmoral crossover graft. This 
kind of approach may avoid the area where the ureter is 
densely bound into the aneurysm or where the bowel is 
bound up against the ancurysm. If you try to tunnel 
through severe inflammation, you can injure the ureter. 
Dr. John W. Smith (Omaha, Neb.). We work in a 
hospital where Dr. Mardis, who first described stents, is the 
senior urologist, so when I had a patient like this that would 
not drain one lddney, I said, "Fix him up, put a stent in." He 
said, "Well, I will do it, but it will not work. Stents only work 
when the ureter has peristalsis." He put it in and, lo and 
behold, it did not work. So the question in my mind is that 
maybe we should be lysing these ureters, because the 
alternative is a nephrostomy. Then you have a hole in the 
body next to your graft that is potentially infected, and we 
do not want to be in that position either. 
Dr. Hallett. In some ways, the ureteral entrapment may 
be an insoluble problem. If one looks at the risk oflysing of 
the ureters in some of these inflammatory areas, I am 
concerned that we may have more trouble with lysis than 
simple stenting. We are not, however, totally preserving the 
renal function by what we currently do in some patients. If  
we could identify more precisely the pathogenesis of inflam- 
matory AAAs, other antiinflammatory agents might help. 
Inflammatory aneurysms have many histochemical features 
similar to giant cell arteritis. 323s A defect in the human 
lymphocytes may play into the abnormal inflammatory 
aneurysm reaction. If we could identify the antigen(s) in 
inflammatory AAAs and why the immune system produces 
such exuberant inflammation, we could progress in our total 
management of these difficult AAAs. 
